Sequential antiretroviral adherence measurement using electronic bottle cap monitors in a cohort of HIV-infected adults

Journal of the International Association of Physicians in AIDS Care

Volumn 11, Issue 2, 2012, Pages 94-97

  Shuter, Jonathan ^a,b   Sarlo, Julie A ^a   Stubbs, Roxann O ^a   Rode, Richard A ^c   Zingman, Barry S ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

adherence; AIDS; HIV; MEMS

Indexed keywords

ATAZANAVIR; DARUNAVIR; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR;

ADULT; ARTICLE; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION EVENT MONITORING SYSTEM; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG PACKAGING; ELECTRONICS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; VIRAL LOAD;

EID: 84859317052     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109711420498     Document Type: Article

References (10)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Int Med. 2000;133(1):21-30. (Pubitemid 30432540)
2. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4): 357-366. (Pubitemid 30182431)
3. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Inf Dis. 2001;33(8):1417-1423. (Pubitemid 32955198)
4. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates below 95%. J Acquir Immune Defic Syndr. 2007;45(1): 4-8. (Pubitemid 46684437)
5. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16(16):2175-2182. (Pubitemid 35387272)
6. Rawlings MK, Thompson MW, Farthing CF, et al. Impact of an educational program on efficacy and adherence with a twicedaily lamivudine/zidovudine/ abacavir regimen in underrespresented HIV-infected patients. J Acquir Immune Defic Syndr. 2003;34(2):174-183. (Pubitemid 37248914)
7. Pariente JJ, Massari V, Reliquet V, et al. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. AIDS. 2007;21(16):2217-2222. (Pubitemid 350287220)
8. Rosenblum M, Deeks S, van der Laan M, Bangsberg DR. The risk for virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One. 2009;4(9):e7196.
9. Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E, Williams AB. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 2005;9(1):103-110. (Pubitemid 40562187)
10. Podsadecki TJ, Vrijens BC, Tousset EP, et al. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials. 2008;9(4): 238-246.